In human neuroendocrine tumors, OPN is overexpressed in patient serum, and during treatment, higher OPN levels (above 200 ng/mL) at initial evaluation predict a worse prognosis, leading to a shorter progression-free survival [17]. The gene discussed is SPP1; the disease is neuroendocrine neoplasm.